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I. BACKGROUND AND STATEMENT OF ISSUES 
This report provides results of a follow-up investigation of the pattern of kidney cancer in the 
South End area of New Bedford.  In July 2003, the Community Assessment Program (CAP) of 
the Center for Environmental Health (CEH) at the Massachusetts Department of Public Health 
(MDPH) completed an evaluation of cancer incidence in the South End area of New Bedford to 
investigate community concerns about the possible role that environmental exposures related to 
the Allegheny Rodney Company (also known as Rodney Metals) and Brittany Dyeing and 
Printing Corporation (a.k.a. Brittany Dye) may play in the incidence of cancer in the 
neighborhoods adjacent to the facilities (ATSDR 2003).  Rodney Metals and Brittany Dye are 
located in the South End area of New Bedford, census tract 6528, on East Rodney French 
Boulevard to the south of Butler Street and east of Swan Street (refer to Figure 1). 
Results of the July 2003 report indicated that the majority of cancer types evaluated occurred 
approximately at or near the expected rate during 1982-1998 in New Bedford census tract 6528 
and, with the exception of kidney cancer, no apparent spatial patterns were observed at the 
neighborhood level.  However, a statistically significant elevation in the incidence of kidney 
cancer occurred among males in this census tract during the most recent time period evaluated 
(i.e., 5 diagnoses observed versus 1.3 expected), 1995-1998, and all five individuals diagnosed 
with kidney cancer during this time were located within close proximity to the Rodney Metals 
and Brittany Dye facilities.  At the time of the initial investigation, available data on smoking 
and occupation were limited, and the possible role of these and other risk factors, such as family 
and medical history, could not be evaluated for these individuals making stronger conclusions 
about environmental etiologic factors difficult at best.  In addition, it was not possible to evaluate 
whether air emissions from the two facilities resulted in the presence of elevated levels of 
chlorinated volatile organic compounds such as trichloroethylene (TCE) in the ambient air 
adjacent to these facilities and, if present, whether human exposure may have occurred in the 
past. 
Based on the findings of the July 2003 report, the MDPH recommended additional follow-up for 
all individuals diagnosed with kidney cancer in New Bedford census tract 6528 since 1982 when 
the Massachusetts Cancer Registry (MCR) began collecting cancer data.  Specifically, 
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opportunities for personal interviews and/or medical records reviews were offered to those 
individuals diagnosed with kidney cancer (or their families), who provided informed consent, to 
determine any possible environmental or other factors that may have contributed to their 
diagnosis.  The purpose of the case interviews was to identify the prevalence of known or 
suspected risk factors among those diagnosed with kidney cancer, to learn more about the pattern 
observed, and to help determine whether it is more or less likely that environmental factors 
related to the two facilities may have played a role in their diagnoses.  The purpose of the 
medical records review was to obtain supplemental information on factors possibly associated 
with their diagnoses. 
It should be noted that present and future air exposure to TCE is not expected since Rodney 
Metals discontinued use of TCE in 1982 and Brittany Dye discontinued use of TCE just prior to 
the release of the 2003 cancer incidence report.  However, due to unpleasant odors and nuisance 
conditions reported by individuals living near the two facilities, the MDPH recommended that 
the Massachusetts Department of Environmental Protection (MDEP) determine any additional 
actions that could reduce potential nuisance impacts to residents in the surrounding 
neighborhood.  As a result, MDEP conducted site visits at the two facilities, and both companies 
have since agreed to work with the Massachusetts Executive Office of Environmental Affairs, 
Office of Technical Assistance, to help identify ways to reduce impacts to the local community. 
This project and the initial July 2003 report were conducted under a cooperative agreement with 
the Agency for Toxic Substances and Disease Registry (ATSDR).  A detailed discussion of the 
history of both Rodney Metals and Brittany Dye, including a review of available environmental 
data, is included in the first report (ATSDR 2003).  The 2003 report is available on the MDPH 
web site at www.mass.gov/dph/ceh.  In addition, a copy of the report is available at the New 
Bedford Free Public Library (Main Library). 
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II. OBJECTIVES 
The objectives of this follow-up investigation were: 
• Using the Massachusetts Cancer Registry (MCR), identify all individuals diagnosed with 
kidney cancer while living in the South End area of New Bedford since 1982 and contact 
them to request participation in personal interviews and/or medical records review. 
• Obtain all available information about known or suspected risk factors for individuals 
diagnosed with kidney cancer (e.g. smoking, occupation, family or medical history) 
through personal interviews and medical records review for those who provide informed 
consent, as well as information available for all cases through the MCR, death records, 
and city resident lists. 
• Evaluate the prevalence of kidney cancer risk factors together with information on length 
of residence and the geographic locations of all cases to help determine whether 
environmental factors related to Rodney Metals and Brittany Dye are more or less likely 
to have played a role in the pattern of kidney cancer observed among residents of New 
Bedford’s South End. 
III. METHODS 
The Commissioner of the MDPH approved this study under provisions outlined in M.G.L. c. 
111, s. 24A, which protects the confidentiality of all information collected as part of this study.  
Under the provision of this statute, the MDPH and all its employees and agents involved in the 
New Bedford Kidney Cancer Follow-up Investigation are prohibited from releasing any 
information provided by study participants or obtained from their medical records in any manner 
that would allow participants to be personally identified.  Furthermore, Section 24A prohibits the 
disclosure or release through a public records request, court subpoena, or any other legal process, 
of any personal or medical information participants provide to the MDPH.  Every effort is made 
to maintain participant confidentiality.  For example, only personnel directly involved with this 
project have access to completed questionnaires, medical records, and computer files.  
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Confidential information and identifiable data collected as a result of this project are archived in 
locked storage files. 
A. Case Definition and Identification 
Cases included all individuals who were diagnosed with kidney cancer and reported to the MCR 
since 1982, when the registry was established, and whose reported address at diagnosis was 
located in the South End of New Bedford (i.e., CT 6528).  We searched data records available 
from the MCR to identify individuals who met these criteria. 
The MCR, a division within the MDPH Center for Health Information, Statistics, Research and 
Evaluation, is a population based surveillance system that has been monitoring cancer incidence 
in the Commonwealth since 1982.  All new diagnoses of cancer among Massachusetts residents 
are required by law to be reported to the MCR within 6 months of the date of diagnosis (M.G.L. 
c.111. s 111b).  Individuals are reported to the MCR based on their reported residence at 
diagnosis, regardless of the hospital or medical facility where they were diagnosed.  In addition, 
Massachusetts residents diagnosed or treated in neighboring states are reported to the MCR 
through reciprocal reporting agreements with 15 states, including Rhode Island, Connecticut, 
New York, Vermont, and New Hampshire. 
For the diagnosis year 2001, the MCR’s total case count was estimated by the North American 
Association of Central Cancer Registries to be complete.  (Completeness for more recent years 
has not yet been estimated.)  Although the MCR data are considered complete through 2001, this 
is an on-going surveillance system that collects reports on a daily basis.  Therefore, it is possible 
for CAP staff to review case reports for more recent years as the MCR file is updated (i.e., 2002-
present).1 
Twelve individuals diagnosed with kidney cancer were identified during the initial investigation, 
which included a review of kidney cancer diagnoses in New Bedford census tract 6528 between 
1982 and 1998.  In the process of conducting this follow-up study, three additional residents 
were identified as having been diagnosed with kidney cancer.  These three individuals were 
                                                 
1 The data summarized here are drawn from data entered on MCR computer files before June 22, 2005.  The 
numbers presented may differ slightly from those published in previous or future reports, reflecting late reported 
cases, address corrections, or other changes based on subsequent details from reporting facilities. 
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diagnosed with kidney cancer after 1998.  Therefore, the case population for this study includes a 
total of 15 individuals diagnosed with kidney cancer between 1982 and 2003 who were reported 
as being residents of New Bedford’s South End at the time of their diagnosis.  As of September 
14, 2005, there were no additional reports to the MCR of kidney cancer diagnoses among 
residents of this area. 
B. Data Collection 
1. Participant recruitment 
Prior to participant recruitment, a search of death records available from the MDPH Registry of 
Vital Records was conducted to determine the vital status of each case.  If a Massachusetts death 
record could not be located, it was assumed that the individual was still living and could be 
contacted directly.  For deceased cases, the informant listed on the death certificate, who was 
considered to be the “next-of-kin,” was contacted to request their participation in the interview 
portion of the study as a proxy for the case and to consent to review of the deceased’s medical 
records. 
Address information was obtained from the MCR for cases and from death records for next-of-
kin.  In addition, searches of city, state, and nationwide directories and the Registry of Motor 
Vehicles database were conducted to confirm or identify current addresses for cases that may 
have relocated since the time of their diagnosis and next-of-kin who may have moved since the 
time of death.  For some individuals, address forwarding information was provided by the U.S. 
Postal Service. 
Fourteen of the 15 individuals diagnosed with kidney cancer and next-of-kin were initially 
contacted by letter in January 2004.  Recruitment letters were written in both English and 
Portuguese to ensure that language would not present a barrier to study participation.  The letters 
reviewed the results of the original investigation, explained the purpose of the current study, and 
requested individuals to agree to be interviewed as part of the New Bedford Kidney Cancer 
Follow-up Investigation and to consent to a medical records review.  Individuals were advised 
that participation in this study was completely voluntary, that they could withdraw from the 
investigation at any time, and that their identity and all information provided to or obtained by 
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the MDPH would be held strictly confidential.  Between February and May 2004, three 
subsequent recruitment mailings reiterating these points were sent to individuals who did not 
respond to the first letter.  The final two recruitment mailings were sent via certified mail with a 
return receipt to verify delivery.  In addition, follow-up telephone calls during the spring and 
summer of 2004 were conducted for individuals whose initial response suggested possible 
misunderstanding of study purpose or procedures.  A check of updated MCR files in June 2005 
identified one additional individual diagnosed with kidney cancer while living in the South End 
area of New Bedford.  In an effort to include this individual as part of the study, a recruitment 
letter was promptly sent by mail requesting their participation in an interview and medical 
records review.   
2. Interviews 
A survey instrument (questionnaire) was developed by CAP staff specifically for the New 
Bedford Kidney Cancer Follow-up Investigation.  This questionnaire covered various topics 
including the case’s kidney cancer diagnosis, medical history, residential history, occupational 
history, lifestyle habits, and family history of cancer.  The majority of questions focused 
specifically on known or suspected risk factors for kidney cancer as identified through published 
medical and scientific journal articles and other texts.  A draft survey instrument was reviewed 
by an occupational and environmental health physician who consults with the MDPH’s CEH and 
recommended revisions were incorporated as appropriate into the final version (see Appendix 
A).  Questionnaires were identical for individuals diagnosed with kidney cancer and next-of-kin, 
with the exception that questions for those diagnosed with kidney cancer were phrased in the 
second person while questions for next-of-kin were phrased in the third person. 
Eight interviews were completed as part of this follow-up investigation.  With one exception, 
interviews were conducted in person and took place at the participants’ homes in New Bedford.  
One participant lived out-of-state and therefore the interview was conducted by telephone. 
Informed consent to participate in interviews was obtained in writing prior to each interview.  
The same CEH staff member conducted all interviews.  Interview length ranged from 45 to 90 
minutes. 
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3. Medical records review 
The purpose of the medical records review was to verify information obtained from the interview 
and to determine the presence of other known or suspected risk factors for kidney cancer among 
cases that may not have been identified in the interview. 
An Authorization for Disclosure of Medical Records was obtained in writing for each 
participant.  Upon informed consent, physicians and/or health care facilities named by the 
participant were contacted by letter to request copies of medical records relevant to the purposes 
of this investigation.  The physicians and/or health care facilities were responsible for copying 
and submitting records to MDPH. 
Medical records were received for all eight individuals who provided informed consent.  It is 
important to note, however, that for some individuals, complete sets of medical records were not 
available. 
4. Other information sources 
The intent and purpose of conducting in-person interviews and medical records reviews was to 
obtain the best quality information available from those diagnosed with kidney cancer or their 
next-of-kin that was not readily available when the 2003 investigation was conducted.  
Supplemental information for these individuals and information on kidney cancer risk factors for 
individuals diagnosed with kidney cancer for which interviews and medical records reviews were 
not possible was sought from alternative sources (i.e., MCR, death records, and city resident 
lists).  These data sources are described below. 
In addition to specific data pertaining to the diagnosis of cancer (e.g., date of diagnosis, primary 
site, and histology classification), the MCR also collects some information regarding risk factors 
for individuals diagnosed with cancer, such as gender, age at diagnosis, smoking history, and 
occupation.  Case-specific information available from the MCR was reviewed for all 15 
individuals diagnosed with kidney cancer, including those who were unable or unwilling to 
consent to an interview and medical records review. 
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Massachusetts death records were retrieved from the Registry of Vital Records at the MDPH 
Center for Health Information, Statistics, Research and Evaluation for all individuals diagnosed 
with kidney cancer who were deceased at the time this follow-up investigation was initiated (n = 
9).  In addition to identifying the individual’s next-of-kin, death records were reviewed for 
supplemental information related to occupation, immediate and underlying cause(s) of death, and 
other significant conditions contributing to death. 
The address at the time of diagnosis for each individual diagnosed with cancer was mapped 
using a computerized geographic information system (GIS) (ESRI 2002).  The geographic 
pattern was determined using a qualitative evaluation of the point pattern of cases in New 
Bedford CT 6528.  In instances where the address information from the MCR was incomplete, 
that is, did not include specific streets or street numbers, efforts were made to research 
individuals’ residence information using telephone books and city residential lists issued within 2 
years of an individual’s diagnosis.  Address information for the eight individuals who were 
interviewed was further confirmed and verified.  In addition, some of the individuals who were 
interviewed reported living previously at other locations in the South End and this information 
was also considered as part of the geographic distribution analysis.  Because of confidentiality 
concerns, maps of individuals diagnosed with kidney cancer cannot be shown.   
Finally, annual city directories and street lists of residents for the city of New Bedford were 
consulted to determine length of residence for those individuals who were not able to be 
interviewed.  Although it is not possible to determine what may have caused any one person’s 
diagnosis with cancer, the length of time in which an individual lived in a particular residence 
can help determine the importance that their location might have in terms of potential exposure 
to an environmental source. 
C. Data Analysis 
Data obtained from the questionnaire, medical records, and other information sources were 
tabulated and analyzed for known or suspected risk factors for kidney cancer or any common 
factors among cases.  In addition, CEH’s consultant occupational and environmental health 
physician reviewed available medical records and summarized information about the kidney 
cancer diagnosis, history of illnesses, use of medications, and other factors relevant to the 
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purpose of this investigation.  Finally, temporal trends, information regarding length of residence 
in the South End and geographic proximity to Rodney Metals and Brittany Dye were considered. 
As described previously, an attempt was made to determine the prevalence of known or 
suspected risk factors for kidney cancer among the case population.  For each of these risk 
factors, the number of cases with the risk factor is reported.  The presence of multiple risk factors 
for several individuals is also discussed, taking into consideration the relative strength of 
association for different risk factors.  Finally, risk factor information, place of residence, and 
length of residence were evaluated together to assess whether the observed pattern appears 
atypical for these cases with respect to established incidence trends in the general population or 
suggests that a common risk factor (environmental or non-environmental) is likely related to 
these diagnoses. 
In accordance with state and federal privacy laws, results are presented as aggregate data only so 
that no participants can be personally identified. 
The results presented here are limited to the available data and therefore should be interpreted 
with caution.  For some cases (e.g., those who participated in an interview and consented to a 
review of their medical records), more information was available.  For others (e.g., those who 
were unable or unwilling to participate in this study), we relied mainly on information available 
from the MCR, death records, and city residential lists.  In addition, inherent limitations in this 
type of analysis and the available data make it impossible to determine the precise causal 
relationships between particular risk factors and the development of cancer or synergistic roles 
that may have played a part in the development of individual cancers.  It is important to stress 
that this type of analysis cannot determine what may have caused any one individual’s cancer. 
IV. RESULTS 
A. Study Participation 
As previously described, the CAP identified 15 individuals who were diagnosed with kidney 
cancer while reported to be living in the South End area of New Bedford since the year 1982 and 
contacted them (or their next-of-kin) to request their participation in the follow-up study.  
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Twelve of these individuals were diagnosed between the years 1982–1998 and identified in the 
2003 report; three others were diagnosed after 1998.  Of the 15 individuals diagnosed with 
kidney cancer since 1982, nine were deceased.  No other residents of the South End have been 
diagnosed with kidney cancer and reported to the MCR as of September 2005.   
As previously mentioned, four study recruitment mailings were conducted in 2004 and one 
additional case was contacted by mail in summer 2005.  Twelve of the 15 individuals (80%) 
responded to the requests for participation in this follow-up study.  Eight of the individuals who 
responded agreed to be interviewed and also provided consent for MDPH to obtain their medical 
records.  One South End resident diagnosed with kidney cancer and family members of three 
other individuals, however, made it clear that they did not want to be interviewed.  Three 
subsequent mailings sent to those participants who did not respond initially did not result in any 
other potential study participants agreeing to be interviewed or consenting to a medical records 
review.  Figure 2 illustrates these participation results. 
B. Evaluation of Kidney Cancer Risk Factor Information 
There are a number of known and suggested risk factors for kidney cancer, including age, 
gender, lifestyle factors such as smoking, environmental and occupational exposures, pre-
existing medical conditions such as hypertension, obesity, and advanced kidney disease, family 
history, and certain inherited genetic conditions.  Some information on kidney cancer risk factors 
available through the MCR (i.e., smoking status, occupation) was evaluated as part of the 2003 
cancer incidence investigation.  However, for some individuals, relevant risk factor information 
was missing or not reported.  In addition, information on other important factors associated with 
development of kidney cancer (i.e., family and medical history) is not routinely collected by the 
MCR. 
The intent and purpose of conducting in-person interviews and medical records reviews was to 
obtain the best quality information available from those diagnosed with kidney cancer or their 
next-of-kin that was not readily available when the 2003 investigation was conducted.  Risk 
factor information collected for the eight individuals who participated in the interview part of the 
follow-up study is summarized below.  In addition, information on kidney cancer risk factors for 
the other individuals diagnosed with kidney cancer for which interviews and medical records 
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reviews were not possible was sought from alternative sources (e.g. MCR, death records, and 
city resident lists).  Where available, information about kidney cancer risk factors from these 
other sources is also presented.  However, for some of the risk factors discussed below, it was 
only possible to present information for the eight individuals for whom interviews or medical 
records review were conducted. 
1. Age and gender distribution 
Kidney cancer most often occurs in the fifth and sixth decades of life (50-70 years age group) 
and occurs about twice as often in males versus females.  The discrepancy in the gender-specific 
incidence of kidney cancer is thought to reflect the fact that men are more likely than women to 
be smokers and to be employed in industries where occupational exposures may be important 
(ACS 2004).  Age and gender information for the South End residents diagnosed with kidney 
cancer was available through the MCR and additionally through the medical records for the eight 
individuals for whom an interview was conducted.  Of the 15 South End residents diagnosed 
with kidney cancer, the ages at diagnosis ranged from 48 to 80 years.  The average age at 
diagnosis was 68 years which is consistent with the established age pattern for this cancer type 
and a higher incidence among older age groups.  Eleven of the 15 individuals diagnosed with 
kidney cancer were men and four were women. 
2. Histology (cell-type) 
The most common type of kidney cancer is renal cell carcinoma, which affects the main part of 
the kidney and accounts for about 90% of all malignant kidney cancers.  Among renal cell 
carcinomas, clear cell carcinomas make up about 70% to 80% of the diagnoses and papillary 
carcinomas make up about 10% to 15% of diagnoses.  In the general population, transitional cell 
carcinomas, which begin in the renal pelvis, comprise about 5% to 10% of all malignant kidney 
cancer diagnoses (ACS 2004). 
Information on the specific types of kidney cancer diagnosed among individuals in the South 
End area of New Bedford was available through the MCR and additionally through the medical 
records for the eight individuals for whom an interview was conducted.  Of the 15 individuals in 
this cohort, the majority (n = 12) were diagnosed with renal cell carcinoma.  In addition, two 
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individuals were diagnosed with transitional cell carcinoma of the renal pelvis and one was 
diagnosed with papillary carcinoma of the renal pelvis.  The observed histology distribution is 
consistent with expected patterns of disease in the general population. 
3. Smoking history 
Cigarette smoking is the most important known risk factor for kidney cancer.  Estimates of the 
increased risk of kidney cancer associated with smoking range from 40% to 100% (ACS 2004; 
NCI 2004).  In both males and females, a statistically significant dose response relationship 
between smoking and this cancer type has been observed (McLaughlin et al. 1996).  That is, a 
greater risk of developing kidney cancer exists among individuals who smoke more. 
Five of the eight individuals diagnosed with kidney cancer for which interviews and medical 
records reviews were conducted were current or former smokers at the time of diagnosis.  For 
these individuals, it is possible that smoking may have played an important role in their kidney 
cancer diagnosis.  The other three individuals were non-smokers; however, it was reported that 
two of the three had lived with a person who smoked.  The association between second-hand 
smoke and the development of kidney cancer is unknown.   
Information on smoking was available from the MCR for three of the seven individuals for 
whom interviews and medical records reviews were not possible.  One was reported to the MCR 
as being a current or former smoker at the time of diagnosis and two were reported as being 
nonsmokers.  Information on smoking history was unknown for the remaining four individuals.   
4. Occupation 
Some studies have suggested that certain environmental and occupational exposures may be 
associated with the development of kidney cancer.  For example, an increased incidence of this 
cancer type has been observed among leather tanners, shoe workers, and workers exposed to 
asbestos.  Coke-oven workers in the iron and steel industries may be at increased risk (NCI 
2004).  In addition, exposure to cadmium, a type of metal, is associated with an increased 
incidence of kidney cancer, particularly among men who smoke.  Workplace exposure to some 
herbicides and organic solvents, such as benzene and TCE, may also increase the risk of this 
cancer (ACS 2004; ATSDR 1997).  More recently, renal cell carcinoma (RCC), the most 
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common type of kidney cancer, has been suggested to be associated with occupational exposure 
to petroleum, tar, and pitch products such as gasoline.  However, studies of oil refinery workers 
and petroleum products distribution workers have not identified a definitive relationship between 
exposure to gasoline or other petroleum products and kidney cancer (Lineham et al. 1997; 
McLaughlin et al. 1996). 
While a person’s occupation or job title cannot provide specific information related to actual 
exposure to workplace chemicals, the information can be helpful in evaluating whether a 
person’s occupation might have played a possible role in their cancer diagnosis.  Of the eight 
individuals who participated in the follow-up study, four were reported to have worked in 
occupations where exposures to chemicals/solvents related to kidney cancer may have been 
possible.   
Some occupational information was also available from the MCR, death records, and resident 
lists for six of the seven South End residents diagnosed with kidney cancer who did not 
participate in the follow-up study.  Of these individuals, four reported working in occupations 
where exposures to chemicals/solvents related to kidney cancer might have occurred.   
For the eight individuals with possible occupational risk factors, occupations included jobs in 
mills and manufacturing environments where exposure to solvents such as benzene or TCE, or 
petroleum may have occurred.  In addition, asbestos exposure was reported for one person. 
Of the 15 South End residents diagnosed with kidney cancer, occupations reported for five 
individuals were not likely to have resulted in exposures that could be related to kidney cancer.  
Occupation was unknown or incomplete for two individuals and therefore the possible role of a 
workplace exposure could not be evaluated.   
5. Medical history 
Hypertension (i.e., high blood pressure) has been linked to kidney cancer.  However, the use of 
diuretics and antihypertensive medications is also associated with an increased risk of kidney 
cancer, and because most people who have high blood pressure are given medications to treat 
their condition, it is not clear whether the disease or the medication is the cause of the increased 
risk (ACS 2004). 
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Individuals (or their next-of-kin) who were interviewed were asked if they had a history of 
hypertension.  Seven of the eight individuals had a history of hypertension.  One individual 
reported no history of hypertension.  Of the seven with a history of hypertension, three reported 
taking medication for the condition.   
No information on a history of hypertension was available for the seven individuals diagnosed 
with kidney cancer who were not able to be interviewed. 
Diuretics are also sometimes used to treat congestive heart failure.  Based on information 
available from death records, congestive heart failure was listed as a contributing cause of death 
for two individuals.  Based on data available through the interview and medical records review, 
one of these two individuals had known hypertension but no known history of medication to treat 
either of these conditions.  An interview was not conducted for the other individual and 
therefore, it is unknown whether this person used diuretics to treat their congestive heart failure. 
Obesity is an important risk factor for kidney cancer.  It is estimated that obesity may be a factor 
in about 20% of individuals who develop kidney cancer (ACS 2004).  According to medical 
records, one of the eight individuals interviewed was obese. 
Heavy use of the pain-reliever phenacetin has been associated with an increased risk of kidney 
cancer in the past.  However, this medication has not been available in the U.S. for over 20 years 
and therefore, is no longer considered a major risk factor for kidney cancer (ACS 2004).  None 
of the eight individuals interviewed reported a history of phenacetin use. 
People with advanced kidney disease (e.g., end-stage renal disease or ESRD) and those who 
have been on long-term kidney dialysis are at increased risk of developing kidney cancer (ACS 
2004; NCI 2004).  Based on the available information, this did not appear to be a factor for any 
of the eight individuals interviewed as part of this study. 
Ionizing radiation may be associated with an increased risk of kidney cancer, but the effects are 
described as weak (McLaughlin et al. 1996).  One of the eight individuals interviewed for this 
study received radiation therapy to treat cancer prior to their kidney cancer diagnosis.  It is 
unknown whether the radiation treatment played a role in the subsequent development of kidney 
cancer in this individual. 
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Finally, certain inherited medical conditions, such as von Hippell-Lindau disease, which is 
characterized by a tendency to develop tumors in multiple organs, and hereditary papillary renal 
cell carcinoma, are associated with an increased risk of developing kidney cancer (ACS 2004).  
Based on a review of medical records, there was no evidence of these inherited conditions among 
the eight individuals who participated in the follow-up study. 
6. Family history 
Family history appears to be an important risk factor in the development of kidney cancer.  
Individuals with a strong family history of this disease, particularly those who have a brother or 
sister with kidney cancer, have a much higher risk of developing kidney cancer themselves (ACS 
2004). 
Little information was available regarding a family history of kidney cancer for most of the 15 
individuals diagnosed with kidney cancer.  One of the eight individuals for whom an interview 
was conducted reported having a family member with kidney cancer.   
Information available through the MCR, death records, and resident lists indicated that two of the 
seven individuals diagnosed with kidney cancer for which interviews were not possible, were 
first-degree relatives.  This suggests that a family history of kidney cancer may have played an 
important role in the diagnoses of these two individuals as well. 
C. Review of Geographic Distribution and Residential History 
While it is not possible to evaluate whether past air emissions of TCE from Rodney Metals and 
Brittany Dye resulted in actual exposure to residents in the adjacent neighborhoods, the 
geographic locations of individuals diagnosed with kidney cancer in proximity to the two 
facilities can be helpful in evaluating potential opportunities for exposure to air emissions.  
Cancer in general has a long period of development or latency period (i.e., the interval between 
first exposure to a disease-causing agent and the appearance of symptoms of the disease [Last 
1995]) that can range from 10 to 30 years and in some cases may be more than 40 to 50 years for 
solid tumors (Bang 1996; Frumkin 1995).  Although it is not possible to determine what may 
have caused any one person’s diagnosis of cancer, the length of time in which an individual lived 
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in a particular residence can also help determine the importance that their location might have in 
terms of exposure to a potential environmental source. 
The 2003 report identified a statistically significant elevation in the incidence of kidney cancer 
among males in census tract 6528 during the most recent time period evaluated, 1995-1998, and 
all five individuals diagnosed with kidney cancer during this time lived within close proximity to 
the Rodney Metals and Brittany Dye facilities.  In addition, several individuals diagnosed with 
kidney cancer in the earlier two time periods (e.g. 1982-1986, 1987-1994) also lived near the two 
companies.  However, at the time of the initial analysis, gaps in the data existed and it was not 
possible to evaluate the geographic locations of cases in the context of other important 
considerations such as length of residence or other kidney cancer risk factors. 
For the current analysis, the geographic proximity of all 15 individuals diagnosed with kidney 
cancer in relation to the two companies was evaluated together with available information on the 
length of time each individual lived in the South End area prior to their diagnosis and the 
presence of known or suspected kidney cancer risk factors.  To evaluate the geographic pattern 
of those diagnosed with kidney cancer, the approximate distance between the address of each 
case and the central location of the two facilities combined was measured.  Information on length 
of residence was obtained directly from those who were interviewed and from city resident lists 
for those who did not participate in the interviews.  As stated previously, some of the individuals 
who were interviewed reported living previously at other locations in the South End and this 
information was also considered when assessing length of residence as part of the geographic 
distribution analysis.  Prior residential information was not available for those individuals who 
did not participate in interviews. 
Eight of the 15 individuals diagnosed with kidney cancer since 1982 lived within approximately 
a quarter of a mile from the two facilities, including five for whom interviews and medical 
records reviews were conducted.  Six of the eight individuals lived at their residence for more 
than 20 years, one individual lived there between 10 and 20 years and one lived there for less 
than 10 years.  In addition to age, six of the eight individuals within a quarter of a mile had at 
least two risk factors and two individuals had at least one risk factor associated with the 
development of kidney cancer.   
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Seven of the 15 individuals diagnosed with kidney cancer since 1982 were located more than a 
quarter of a mile from Rodney Metals and Brittany Dye.  One of these individuals was reported 
to have developed kidney cancer prior to moving to the area2 and therefore it is very unlikely that 
environmental factors related to the two facilities would have played a role in this person’s 
diagnosis.  Five of the remaining individuals lived at their residence for more than 20 years, and 
one lived there less than 10 years.  In addition to age, two of these six individuals were reported 
to have at least two risk factors and two individuals had at least one risk factor associated with 
kidney cancer.  The two remaining individuals were not able to be interviewed, so the possible 
role of kidney cancer risk factors could not be fully evaluated.  However, according to the MCR 
data, one of these individuals was reported as a non-smoker and available occupational 
information did not indicate employment in a job likely related to kidney cancer. 
D. Temporal Evaluation 
Dates of diagnosis for the 15 South End residents with kidney cancer were evaluated together 
with information on risk factors for the disease collected from the interviews, medical records 
review, and from alternative sources (where necessary) to assess any time trends that might be 
present since 1982.  Other than the statistically significant elevation in kidney cancer reported for 
males during the 1995-1998 time period in the 2003 report, there were no other notable time 
trends among kidney cancer cases diagnosed between 1982 and the present.  That is, no more 
than two diagnoses were reported in any given year and no increasing or decreasing trends in 
kidney cancer were observed.  Three of the five males diagnosed during the 1995-1998 time 
period had at least one kidney cancer risk factor other than age, and the other two had more than 
one. 
V. DISCUSSION 
The 2003 health consultation identified a statistically significant elevation in the incidence of 
kidney cancer among males in census tract 6528. During the most recent time period evaluated, 
1995-1998, all five individuals diagnosed with kidney cancer during this time lived within close 
                                                 
2 Although the address reported to the MCR for this individual was a South End residence, information available 
from a close relative indicated that the kidney cancer diagnosis actually occurred prior to the family’s relocation to 
New Bedford.  This individual did not participate in an interview. 
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proximity to the Rodney Metals and Brittany Dye facilities.  In addition, several individuals 
diagnosed with kidney cancer in the earlier two time periods (e.g. 1982-1986, 1987-1994) also 
lived near the two companies.  At the time of the initial investigation, available data on smoking 
and occupation were limited, and the possible role of these and other important risk factors for 
kidney cancer, such as family and medical history, could not be evaluated for these individuals.   
For the current study, all individuals diagnosed with kidney cancer while reported to be living in 
the South End area of New Bedford since 1982, were identified using the MCR and they or their 
next-of-kin were contacted to request participation in personal interviews and/or medical records 
review.  The purpose of the follow-up study was to identify the prevalence of any known or 
suspected risk factors among individuals diagnosed with kidney cancer (e.g. smoking, 
occupation, family or medical history) and to learn more about the pattern observed in the 2003 
cancer incidence investigation.   It is unknown whether individuals diagnosed with kidney cancer 
were exposed to air emissions of TCE from Rodney Metals and Brittany Dye in the past.  To 
evaluate whether environmental factors may have played a greater or lesser role in kidney cancer 
diagnosed among individuals located in close proximity to the two companies, the prevalence of 
kidney cancer risk factors and information on length of residence were evaluated together with 
information on the geographic locations of cases.   
Twelve of the 15 individuals contacted for participation in the study responded to the MDPH, 
and of those, eight agreed to be interviewed and consented to medical records review.  Although 
interviews were not possible for the other seven cases, some important information related to 
kidney cancer risk factors (e.g., age, smoking status, occupation), as well as information on their 
length of residence, was available through the MCR, death records, and town resident lists. 
Based on the evaluation of all available information, one of the 15 individuals was confirmed as 
having no known or suggested kidney cancer risk factors other than age.  No information was 
available related to kidney cancer risk factors for two individuals with the disease; however, one 
was reportedly diagnosed prior to moving to the area, and the length of residence for the other 
was less than ten years.  Twelve of the 15 individuals with kidney cancer had at least one known 
or suspected kidney cancer risk factor other than age, and of these, eight had more than one.  
Individuals who lived in closer proximity to Rodney Metals and Brittany Dye (i.e., within 
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approximately a quarter of a mile) did not appear to have fewer kidney cancer risk factors 
compared with those who lived farther away. 
A review of medical records for the eight individuals who were interviewed was conducted by an 
occupational/environmental physician to identify any unique or unusual traits that were common 
among the individuals but that differ from those expected in the general population of patients 
suffering from kidney cancer.  Based on this review, no unusual traits were identified that would 
suggest that the eight individuals were different from what would be expected.     
VI. CONCLUSIONS / RECOMMENDATIONS 
Based on the available information, those individuals diagnosed with kidney cancer who lived 
closer to Rodney Metals and Brittany Dye had no fewer risk factors associated with the 
development of kidney cancer than South End residents with kidney cancer who lived farther 
away.  Although interviews were not possible for seven individuals and some information was 
incomplete, multiple risk factors associated with the development of kidney cancer were 
identified for the majority of the 15 individuals diagnosed with kidney cancer while living in the 
South End area of New Bedford.  Thus, despite the geographic pattern observed in the 2003 
investigation, the existence of other risk factors important to the development of kidney cancer 
among individuals living in close proximity to the two companies makes it less likely that 
environmental exposures played a primary role in the development of kidney cancer.  However, 
the majority of the 15 individuals were long-time residents of the area, and therefore the possible 
role of environmental exposure as a contributing factor in the development of kidney cancer 
among those living near the two facilities cannot be ruled out.   
As a result of these findings, the MDPH recommends no further follow-up regarding kidney 
cancer among these 15 South End residents at this time.  However, the incidence of this cancer 
type will continue to be monitored for New Bedford as MCR data for additional years become 
available.  In addition, the MDPH supports continuing efforts of the Massachusetts Department 
of Environmental Protection to address and help minimize nuisance impacts on behalf of the 
local community associated with emissions from Rodney Metals and Brittany Dye.  
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Case Questionnaire 
 
 
 
 
 
February 2004 
Interview Date:____________________________ ID: ______ 
Interview Time Start:_________ End: __________ 
Interviewer Name: _________________________ 
A-3 
 
Interviewer should greet the participant and introduce himself. 
 
Before we start, I would like to confirm some information with you to make sure our records are 
accurate. 
 
Name:  _____________________ 
 
Address: _____________________ 
  
  _____________________ 
 
Phone #: (h) __________________ 
 
  (w) __________________ 
 
 
Thank you for agreeing to participate in this study to help the Massachusetts Department of 
Public Health evaluate issues related to kidney cancer in the South End of New Bedford.  Since 
little is known about the causes of kidney cancer, I’ll be asking you questions to complete a 
detailed questionnaire.  The questions will be mainly about your kidney cancer diagnosis, your 
personal medical history, your family’s history of cancer, and where you lived and worked 
before you were diagnosed with cancer.  Do you have any specific questions before we move 
forward? 
Let me remind you that your cooperation is completely voluntary and a very important 
contribution to this study.  You do have the option to refuse to answer any questions at any time 
during this interview.  All information collected in this study will be kept in the strictest 
confidence in accordance with Massachusetts General Laws.  No use will be made of 
information that would identify you to anyone outside this project. 
Feel free to take as much time as you need to answer these questions.  Some of the questions 
concern events that took place many years ago. 
Please answer the questions as completely and carefully as you can.  If there are any questions 
you do not fully understand, please let me know.  If you are not sure of an answer to a specific 
question, please say so.  Or if you are uncomfortable answering a specific question, please let me 
know as well. 
As a last note, some of the questions may seem repetitive and sometimes it may be frustrating to 
hear the same question asked a number of times, but please bear with me.  We want to make sure 
we get the most complete and accurate information possible from each participant. 
Let’s begin. 
ID: ____ 
 
A-4 
A. Personal Information 
Gender (do not ask): [  ] MALE [  ] FEMALE 
First I’d like to ask some background questions. 
1. What is your date of birth? __/__/____ (mm/dd/yyyy) 
2. What was the date a doctor first told you that you had kidney cancer? 
__/__/____ (mm/dd/yyyy) 
3. Did you have tumors in one or both kidneys? 
[  ] ONE KIDNEY [  ] DK 
[  ] TWO KIDNEYS [  ] REF 
4. Not including the kidney cancer diagnosed on {__/__/____}, were you ever told by a 
doctor that you had any other cancer? 
[  ] NO   [  ] DK 
[  ] YES (ask a & b) [  ] REF 
a. If YES, was the cancer diagnosed before or after the kidney cancer 
diagnosis mentioned already? 
[  ] BEFORE [  ] BOTH BEFORE AND AFTER 
[  ] AFTER [  ] DK 
b. Not including the kidney cancer diagnosed on {__/__/____}, for each 
separate cancer diagnosis, please note the type of cancer and the date of 
diagnosis. 
Cancer Type: _____________________ DOD: __/__/____ (mm/dd/yyyy) 
Cancer Type: _____________________ DOD: __/__/____ (mm/dd/yyyy) 
Cancer Type: _____________________ DOD: __/__/____ (mm/dd/yyyy) 
Cancer Type: _____________________ DOD: __/__/____ (mm/dd/yyyy) 
Cancer Type: _____________________ DOD: __/__/____ (mm/dd/yyyy) 
ID: ____ 
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5. What is your height? 
Height: ____________________ 
[  ] DK 
[  ] REF 
6. What was your average weight approximately one year before you were first 
diagnosed with kidney cancer? 
Average weight: ____________________ 
[  ] DK 
[  ] REF 
7. Which of the following best characterizes your general diet (i.e., averaged over time) 
before you were diagnosed with kidney cancer? 
[  ] Vegetarian or vegan 
[  ] High in fruits and vegetables 
[  ] High in carbohydrates (e.g., pasta, breads, rice) 
[  ] High in protein (e.g., meats, animal fats, milk products, margarine, oils) 
[  ] High in fat 
[  ] Balanced (i.e., combination of fruits, vegetables, carbohydrates, protein, & 
dairy) 
[  ] Other: ___________________________________________________________ 
[  ] DK 
[  ] REF 
 
ID: ____ 
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B. Pre-Existing Medical Conditions and Use of Medications 
Now I’m going to ask you some questions about your personal medical history. 
1. Before you were diagnosed with kidney cancer, had a doctor ever told you that you 
had a kidney defect; that is, something wrong with the shape or structure of the 
kidney? 
[  ] NO   [  ] DK 
[  ] YES (ask a & b) [  ] REF 
a. If YES, which of the following kidney defects did you have? 
[  ] large kidneys 
[  ] horseshoe kidney (also called U-shaped or L-shaped kidneys) 
[  ] hereditary or familial renal oncocytoma 
[  ] other: ______________________________ 
[  ] DK 
[  ] REF 
b. What was the date of diagnosis for this condition? 
__/__/____ (mm/dd/yyyy) 
2. Before you were diagnosed with kidney cancer, had a doctor ever told you that you 
had kidney disease; that is, something wrong with the function or mechanism of the 
kidney? 
[  ] NO   [  ] DK 
[  ] YES (ask a & b) [  ] REF 
a. If YES, which of the following kidney diseases did you have? 
[  ] polycystic kidney disease 
[  ] acquired cystic kidney disease 
[  ] End Stage Renal Disease (ESRD) or End Stage Kidney Disease 
[  ] other: ______________________________ 
[  ] DK 
[  ] REF 
ID: ____ 
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b. What was the date of diagnosis for this disease? 
__/__/____ (mm/dd/yyyy) 
3. Before you were diagnosed with kidney cancer, had a doctor ever told you that you 
had a specific genetic or hereditary condition? 
[  ] NO   [  ] DK 
[  ] YES (ask a & b) [  ] REF 
a. If YES, which of the following genetic conditions did you have? 
[  ] von Hippel-Lindau disease 
[  ] tuberous sclerosis  
[  ] other: ______________________________ 
b. What was the date of diagnosis for this genetic condition? 
__/__/____ (mm/dd/yyyy) 
4. Before you were diagnosed with kidney cancer, had a doctor ever told you that you 
had hypertension or high blood pressure? 
[  ] NO   [  ] DK 
[  ] YES (ask a) [  ] REF 
a. What was the date of diagnosis? __/__/____ (mm/dd/yyyy) 
5. Before you were diagnosed with kidney cancer, had a doctor ever told you that you 
had congestive heart failure (CHF)? 
[  ] NO   [  ] DK 
[  ] YES (ask a) [  ] REF 
a. What was the date of this diagnosis? __/__/____ (mm/dd/yyyy) 
ID: ____ 
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6. Before you were diagnosed with kidney cancer, had a doctor ever told you that you 
had any other serious medical condition? 
[  ] NO   [  ] DK 
[  ] YES (ask a & b) [  ] REF 
a. What was the condition? _________________________________ 
b. What was the date of diagnosis? __/__/____ (mm/dd/yyyy) 
7. Before you were diagnosed with kidney cancer, did you ever receive dialysis 
treatment for kidney disease? 
[  ] NO  [  ] DK 
[  ] YES [  ] REF 
8. Before you were diagnosed with kidney cancer, did you ever have a kidney 
transplant? 
[  ] NO  [  ] DK 
[  ] YES [  ] REF 
9. Before you were diagnosed with kidney cancer, had you ever taken medications to 
relieve pain such as Phenacetin (a drug no longer sold in the U.S.), aspirin, and 
acetaminophen on a regular basis? 
[  ] NO    [  ] DK 
[  ] YES (ask a, b, & c) [  ] REF 
a. What was the name of the medication? ____________________________ 
b. How many times a week did you take this medication? _______________ 
c. For how many years did you take this medication? ___________________ 
ID: ____ 
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10. Before you were diagnosed with kidney cancer, had you ever taken diuretics or 
antihypertensives (medications used for the treatment of high blood pressure or 
congestive heart failure) on a regular basis? 
[  ] NO    [  ] DK 
[  ] YES (ask a, b, & c) [  ] REF 
a. What was the name of the medication? ____________________________ 
b. How many times a week did you take this medication? _______________ 
c. For how many years did you take this medication? ___________________ 
11. Before you were diagnosed with kidney cancer, had you ever received radiation 
therapy to treat an illness or condition (e.g., cancer), not including diagnostic or 
routine X-rays? 
[  ] NO   [  ] DK 
[  ] YES (ask a) [  ] REF 
a. If YES, what was the treatment for? ___________________________ 
ID: ____ 
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C. Tobacco Smoke Exposure 
1. Before you were diagnosed with kidney cancer, had you ever smoked tobacco (e.g., 
cigarettes, pipes, or cigars)? 
[  ] NO   [  ] DK 
[  ] YES (ask a & b) [  ] REF 
a. Approximately how many packs of cigarettes (or number of pipes or cigars) 
did you smoke per week? 
____________________________________________ 
b. For how many years did you smoke? 
_________ years 
2. Before you were diagnosed with kidney cancer, had you ever lived with someone who 
smoked? 
[  ] NO   [  ] DK 
[  ] YES (ask a & b) [  ] REF 
a. Approximately how many packs of cigarettes (or number of pipes or cigars) 
did he/she smoke per week? 
______________________________________________ 
b. For how many years did he/she smoke while you were living there? 
_________ years 
ID: ____ 
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D. Family History of Cancer 
Now I’d like to ask some questions about your family history of cancer. 
1. Has anyone in your family ever been diagnosed with renal cell carcinoma?  Please 
consider parents, siblings, half-siblings, children, grandparents, aunts, and uncles related 
to you by blood. 
[  ] NO   [  ] DK 
[  ] YES (ask a & b) [  ] REF 
a. What was their relation to you? _________________________ 
b. How old were they when they were diagnosed? ____________ 
2. Has anyone in your family ever been diagnosed with kidney cancer? 
[  ] NO   [  ] DK 
[  ] YES (ask a & b) [  ] REF 
a. What was their relation to you? ________________________ 
b. How old were they when they were diagnosed? ___________ 
3. Has anyone in your family ever been diagnosed with any other type of cancer? 
[  ] NO    [  ] DK 
[  ] YES (ask a, b, & c) [  ] REF 
a. What was the (first/next) 
family member’s relation to 
you? 
b.  What cancer type were they 
diagnosed with? 
c.  How old were 
they when they 
were diagnosed? 
   
   
   
   
ID: ____ 
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a. What was the (first/next) 
family member’s relation to 
you? 
b.  What cancer type were they 
diagnosed with? 
c.  How old were 
they when they 
were diagnosed? 
   
   
   
   
   
   
   
   
 
ID: ____ 
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E. Occupational History 
1. Before you were diagnosed with kidney cancer, did you ever work a job as a . . . ? (repeat 
for each of the following jobs) 
  a. How many years did you 
work this job? 
Leather tanner [  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
 
Shoe worker [  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
 
Asbestos worker [  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
 
Shipyard worker [  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
 
Construction worker [  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
 
Coke oven worker or 
steel worker 
[  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
 
Oil refinery worker [  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
 
Laundry worker or dry 
cleaner 
[  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
 
ID: ____ 
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2. Before you were diagnosed with kidney cancer, did you ever work a job in which you 
may have used or been exposed to any of the following chemicals or products? 
  a. What was the 
job? 
b. For how 
many years did 
you work there? 
Asbestos [  ] NO 
[  ] YES (ask a, b) 
[  ] DK 
[  ] REF 
  
Cadmium [  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
  
Organic solvents 
(e.g., 
trichloroethylene 
or TCE) 
[  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
  
Coke oven 
emissions 
[  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
  
Petroleum, tar, 
& pitch products 
[  ] NO 
[  ] YES (ask a) 
[  ] DK 
[  ] REF 
  
ID: ____ 
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3. Now I would like to ask you about all the jobs you held for at least 6 months before you were diagnosed with kidney cancer. 
Job 
# 
a. What was the name 
and address of the 
employer? 
b. What did they make or 
what service did they 
provide? 
c. What were your main 
duties? 
d.  How many years 
did you work there? 
1 Name:_______________ 
Address:_____________
____________________ 
____________________ 
   
2 Name:_______________ 
Address:_____________
____________________ 
____________________ 
   
3 Name:_______________ 
Address:_____________
____________________ 
____________________ 
   
4 Name:_______________ 
Address:_____________
____________________ 
____________________ 
   
ID: ____ 
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Job 
# 
a. What was the name 
and address of the 
employer? 
b. What did they make or 
what service did they 
provide? 
c. What were your main 
duties? 
d.  How many years 
did you work there? 
5 Name:_______________ 
Address:_____________
____________________ 
____________________ 
   
6 Name:_______________ 
Address:_____________
____________________ 
____________________ 
   
7 Name:_______________ 
Address:_____________
____________________ 
____________________ 
   
8 Name:_______________ 
Address:_____________
____________________ 
____________________ 
   
9 Name:_______________ 
Address:_____________
____________________ 
____________________ 
   
 
ID: ____ 
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F. Residential History 
1. Now I’d like to ask you about the places you lived before you were diagnosed with kidney cancer. 
Res 
# 
a. What was the street address of the (first/next) 
place you lived? 
b. What year did you start and end 
residence at this address? 
1 ______________________________________ 
Street No. & Name 
______________________________________ 
Town & State 
Start year: _______ 
End year: _______ 
2 ______________________________________ 
Street No. & Name 
______________________________________ 
Town & State 
Start year: _______ 
End year: _______ 
3 ______________________________________ 
Street No. & Name 
______________________________________ 
Town & State 
Start year: _______ 
End year: _______ 
4 ______________________________________ 
Street No. & Name 
______________________________________ 
Town & State 
Start year: _______ 
End year: _______ 
ID: ____ 
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Res 
# 
a. What was the street address of the (first/next) 
place you lived? 
b. What year did you start and end 
residence at this address? 
5 ______________________________________ 
Street No. & Name 
______________________________________ 
Town & State 
Start year: _______ 
End year: _______ 
6 ______________________________________ 
Street No. & Name 
______________________________________ 
Town & State 
Start year: _______ 
End year: _______ 
7 ______________________________________ 
Street No. & Name 
______________________________________ 
Town & State 
Start year: _______ 
End year: _______ 
8 ______________________________________ 
Street No. & Name 
______________________________________ 
Town & State 
Start year: _______ 
End year: _______ 
9 ______________________________________ 
Street No. & Name 
______________________________________ 
Town & State 
Start year: _______ 
End year: _______ 
ID: ____ 
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G. General Comments 
1. Considering the types of questions we have asked, is there anything else you feel we 
should know? 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
____________________________________________________________________ 
 
That concludes the interview.  I would like to thank you again for taking the time to answer 
these questions.  You have been very helpful.  If you have any questions or concerns about 
the study, or any additional comments, please feel free to contact staff in the Community 
Assessment Program of the Massachusetts Department of Public Health at (617) 624-5757. 
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ATSDR Glossary of Terms 
 
The Agency for Toxic Substances and Disease Registry (ATSDR) is a federal public 
health agency with headquarters in Atlanta, Georgia, and 10 regional offices in the 
United States. ATSDR's mission is to serve the public by using the best science, taking 
responsive public health actions, and providing trusted health information to prevent 
harmful exposures and diseases related to toxic substances. ATSDR is not a regulatory 
agency, unlike the U.S. Environmental Protection Agency (EPA), which is the federal 
agency that develops and enforces environmental laws to protect the environment and 
human health. This glossary defines words used by ATSDR in communications with the 
public. It is not a complete dictionary of environmental health terms. If you have 
questions or comments, call ATSDR's toll-free telephone number, 1-888-42-ATSDR (1-
888-422-8737). 
 
 
General Terms 
 
Absorption  
The process of taking in. For a person or an animal, absorption is the process of a 
substance getting into the body through the eyes, skin, stomach, intestines, or lungs.  
 
Acute  
Occurring over a short time [compare with chronic].  
 
Acute exposure  
Contact with a substance that occurs once or for only a short time (up to 14 days) 
[compare with intermediate duration exposure and chronic exposure].  
 
Additive effect  
A biologic response to exposure to multiple substances that equals the sum of responses 
of all the individual substances added together [compare with antagonistic effect and 
synergistic effect].  
 
Adverse health effect  
A change in body function or cell structure that might lead to disease or health problems  
 
Aerobic  
Requiring oxygen [compare with anaerobic].  
 
Ambient  
Surrounding (for example, ambient air).  
 
Anaerobic  
Requiring the absence of oxygen [compare with aerobic].  
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Analyte  
A substance measured in the laboratory. A chemical for which a sample (such as water, 
air, or blood) is tested in a laboratory. For example, if the analyte is mercury, the 
laboratory test will determine the amount of mercury in the sample.  
 
Analytic epidemiologic study  
A study that evaluates the association between exposure to hazardous substances and 
disease by testing scientific hypotheses.  
 
Antagonistic effect  
A biologic response to exposure to multiple substances that is less than would be 
expected if the known effects of the individual substances were added together [compare 
with additive effect and synergistic effect].  
 
Background level  
An average or expected amount of a substance or radioactive material in a specific 
environment, or typical amounts of substances that occur naturally in an environment.  
 
Biodegradation  
Decomposition or breakdown of a substance through the action of microorganisms (such 
as bacteria or fungi) or other natural physical processes (such as sunlight).  
 
Biologic indicators of exposure study  
A study that uses (a) biomedical testing or (b) the measurement of a substance [an 
analyte], its metabolite, or another marker of exposure in human body fluids or tissues to 
confirm human exposure to a hazardous substance [also see exposure investigation].  
 
Biologic monitoring  
Measuring hazardous substances in biologic materials (such as blood, hair, urine, or 
breath) to determine whether exposure has occurred. A blood test for lead is an example 
of biologic monitoring.  
 
Biologic uptake  
The transfer of substances from the environment to plants, animals, and humans.  
 
Biomedical testing  
Testing of persons to find out whether a change in a body function might have occurred 
because of exposure to a hazardous substance.  
 
Biota  
Plants and animals in an environment. Some of these plants and animals might be sources 
of food, clothing, or medicines for people.  
 
Body burden  
The total amount of a substance in the body. Some substances build up in the body 
because they are stored in fat or bone or because they leave the body very slowly.  
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CAP [see Community Assistance Panel.]  
 
Cancer  
Any one of a group of diseases that occur when cells in the body become abnormal and 
grow or multiply out of control.  
 
Cancer risk  
A theoretical risk for getting cancer if exposed to a substance every day for 70 years (a 
lifetime exposure). The true risk might be lower.  
 
Carcinogen  
A substance that causes cancer.  
 
Case study  
A medical or epidemiologic evaluation of one person or a small group of people to gather 
information about specific health conditions and past exposures.  
 
Case-control study  
A study that compares exposures of people who have a disease or condition (cases) with 
people who do not have the disease or condition (controls). Exposures that are more 
common among the cases may be considered as possible risk factors for the disease.  
 
CAS registry number  
A unique number assigned to a substance or mixture by the American Chemical Society 
Abstracts Service. 
 
Central nervous system  
The part of the nervous system that consists of the brain and the spinal cord.  
 
CERCLA [see Comprehensive Environmental Response, Compensation, and Liability 
Act of 1980]  
 
Chronic  
Occurring over a long time [compare with acute].  
 
Chronic exposure  
Contact with a substance that occurs over a long time (more than 1 year) [compare with 
acute exposure and intermediate duration exposure]  
 
Cluster investigation 
A review of an unusual number, real or perceived, of health events (for example, reports 
of cancer) grouped together in time and location. Cluster investigations are designed to 
confirm case reports; determine whether they represent an unusual disease occurrence; 
and, if possible, explore possible causes and contributing environmental factors.  
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Community Assistance Panel (CAP)  
A group of people from a community and from health and environmental agencies who 
work with ATSDR to resolve issues and problems related to hazardous substances in the 
community. CAP members work with ATSDR to gather and review community health 
concerns, provide information on how people might have been or might now be exposed 
to hazardous substances, and inform ATSDR on ways to involve the community in its 
activities.  
 
Comparison value (CV)  
Calculated concentration of a substance in air, water, food, or soil that is unlikely to cause 
harmful (adverse) health effects in exposed people. The CV is used as a screening level 
during the public health assessment process. Substances found in amounts greater than 
their CVs might be selected for further evaluation in the public health assessment 
process.  
 
Completed exposure pathway [see exposure pathway].  
 
Comprehensive Environmental Response, Compensation, and Liability Act of 1980 
(CERCLA)  
CERCLA, also known as Superfund, is the federal law that concerns the removal or 
cleanup of hazardous substances in the environment and at hazardous waste sites. 
ATSDR, which was created by CERCLA, is responsible for assessing health issues and 
supporting public health activities related to hazardous waste sites or other environmental 
releases of hazardous substances. This law was later amended by the Superfund 
Amendments and Reauthorization Act (SARA). 
 
 
Concentration  
The amount of a substance present in a certain amount of soil, water, air, food, blood, 
hair, urine, breath, or any other media.  
 
Contaminant  
A substance that is either present in an environment where it does not belong or is present 
at levels that might cause harmful (adverse) health effects.  
 
Delayed health effect  
A disease or an injury that happens as a result of exposures that might have occurred in 
the past.  
 
Dermal  
Referring to the skin. For example, dermal absorption means passing through the skin.  
 
Dermal contact  
Contact with (touching) the skin [see route of exposure].  
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Descriptive epidemiology  
The study of the amount and distribution of a disease in a specified population by person, 
place, and time.  
 
Detection limit  
The lowest concentration of a chemical that can reliably be distinguished from a zero 
concentration.  
 
Disease prevention  
Measures used to prevent a disease or reduce its severity.  
 
Disease registry  
A system of ongoing registration of all cases of a particular disease or health condition in 
a defined population.  
 
DOD  
United States Department of Defense.  
 
DOE  
United States Department of Energy.  
 
Dose (for chemicals that are not radioactive)  
The amount of a substance to which a person is exposed over some time period. Dose is a 
measurement of exposure. Dose is often expressed as milligram (amount) per kilogram (a 
measure of body weight) per day (a measure of time) when people eat or drink 
contaminated water, food, or soil. In general, the greater the dose, the greater the 
likelihood of an effect. An "exposure dose" is how much of a substance is encountered in 
the environment. An "absorbed dose" is the amount of a substance that actually got into 
the body through the eyes, skin, stomach, intestines, or lungs.  
 
Dose (for radioactive chemicals)  
The radiation dose is the amount of energy from radiation that is actually absorbed by the 
body. This is not the same as measurements of the amount of radiation in the 
environment.  
 
Dose-response relationship  
The relationship between the amount of exposure [dose] to a substance and the resulting 
changes in body function or health (response).  
 
Environmental media  
Soil, water, air, biota (plants and animals), or any other parts of the environment that can 
contain contaminants.  
 
Environmental media and transport mechanism  
Environmental media include water, air, soil, and biota (plants and animals). Transport 
mechanisms move contaminants from the source to points where human exposure can 
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occur. The environmental media and transport mechanism is the second part of an 
exposure pathway.  
 
EPA  
United States Environmental Protection Agency.  
 
Epidemiologic surveillance [see Public health surveillance]. 
 
Epidemiology  
The study of the distribution and determinants of disease or health status in a population; 
the study of the occurrence and causes of health effects in humans.  
 
Exposure  
Contact with a substance by swallowing, breathing, or touching the skin or eyes. 
Exposure may be short-term [acute exposure], of intermediate duration, or long-term 
[chronic exposure].  
 
Exposure assessment  
The process of finding out how people come into contact with a hazardous substance, 
how often and for how long they are in contact with the substance, and how much of the 
substance they are in contact with.  
 
Exposure-dose reconstruction  
A method of estimating the amount of people's past exposure to hazardous substances. 
Computer and approximation methods are used when past information is limited, not 
available, or missing.  
 
Exposure investigation  
The collection and analysis of site-specific information and biologic tests (when 
appropriate) to determine whether people have been exposed to hazardous substances.  
 
Exposure pathway  
The route a substance takes from its source (where it began) to its end point (where it 
ends), and how people can come into contact with (or get exposed to) it. An exposure 
pathway has five parts: a source of contamination (such as an abandoned business); an 
environmental media and transport mechanism (such as movement through 
groundwater); a point of exposure (such as a private well); a route of exposure (eating, 
drinking, breathing, or touching), and a receptor population (people potentially or 
actually exposed). When all five parts are present, the exposure pathway is termed a 
completed exposure pathway.  
 
Exposure registry  
A system of ongoing followup of people who have had documented environmental 
exposures.  
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Feasibility study  
A study by EPA to determine the best way to clean up environmental contamination. A 
number of factors are considered, including health risk, costs, and what methods will 
work well.  
 
Geographic information system (GIS)  
A mapping system that uses computers to collect, store, manipulate, analyze, and display 
data. For example, GIS can show the concentration of a contaminant within a community 
in relation to points of reference such as streets and homes.  
 
Grand rounds  
Training sessions for physicians and other health care providers about health topics.  
 
Groundwater  
Water beneath the earth's surface in the spaces between soil particles and between rock 
surfaces [compare with surface water].  
 
Half-life (t½)  
The time it takes for half the original amount of a substance to disappear. In the 
environment, the half-life is the time it takes for half the original amount of a substance 
to disappear when it is changed to another chemical by bacteria, fungi, sunlight, or other 
chemical processes. In the human body, the half-life is the time it takes for half the 
original amount of the substance to disappear, either by being changed to another 
substance or by leaving the body. In the case of radioactive material, the half life is the 
amount of time necessary for one half the initial number of radioactive atoms to change 
or transform into another atom (that is normally not radioactive). After two half lives, 
25% of the original number of radioactive atoms remain.  
 
Hazard  
A source of potential harm from past, current, or future exposures.  
 
Hazardous Substance Release and Health Effects Database (HazDat)  
The scientific and administrative database system developed by ATSDR to manage data 
collection, retrieval, and analysis of site-specific information on hazardous substances, 
community health concerns, and public health activities.  
 
Hazardous waste  
Potentially harmful substances that have been released or discarded into the environment.  
 
Health consultation  
A review of available information or collection of new data to respond to a specific 
health question or request for information about a potential environmental hazard. Health 
consultations are focused on a specific exposure issue. Health consultations are therefore 
more limited than a public health assessment, which reviews the exposure potential of 
each pathway and chemical [compare with public health assessment].  
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Health education  
Programs designed with a community to help it know about health risks and how to 
reduce these risks.  
 
Health investigation  
The collection and evaluation of information about the health of community residents. 
This information is used to describe or count the occurrence of a disease, symptom, or 
clinical measure and to evaluate the possible association between the occurrence and 
exposure to hazardous substances.  
 
Health promotion  
The process of enabling people to increase control over, and to improve, their health.  
 
Health statistics review  
The analysis of existing health information (i.e., from death certificates, birth defects 
registries, and cancer registries) to determine if there is excess disease in a specific 
population, geographic area, and time period. A health statistics review is a descriptive 
epidemiologic study.  
 
Indeterminate public health hazard  
The category used in ATSDR's public health assessment documents when a professional 
judgment about the level of health hazard cannot be made because information critical to 
such a decision is lacking.  
 
Incidence  
The number of new cases of disease in a defined population over a specific time period 
[contrast with prevalence].  
 
Ingestion  
The act of swallowing something through eating, drinking, or mouthing objects. A 
hazardous substance can enter the body this way [see route of exposure].  
 
Inhalation  
The act of breathing. A hazardous substance can enter the body this way [see route of 
exposure].  
 
Intermediate duration exposure  
Contact with a substance that occurs for more than 14 days and less than a year [compare 
with acute exposure and chronic exposure].  
 
In vitro  
In an artificial environment outside a living organism or body. For example, some 
toxicity testing is done on cell cultures or slices of tissue grown in the laboratory, rather 
than on a living animal [compare with in vivo].  
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In vivo  
Within a living organism or body. For example, some toxicity testing is done on whole 
animals, such as rats or mice [compare with in vitro].  
 
Lowest-observed-adverse-effect level (LOAEL)  
The lowest tested dose of a substance that has been reported to cause harmful (adverse) 
health effects in people or animals.  
 
Medical monitoring  
A set of medical tests and physical exams specifically designed to evaluate whether an 
individual's exposure could negatively affect that person's health.  
 
Metabolism  
The conversion or breakdown of a substance from one form to another by a living 
organism.  
 
Metabolite  
Any product of metabolism.  
 
mg/kg  
Milligram per kilogram.  
 
mg/cm2  
Milligram per square centimeter (of a surface).  
 
mg/m3  
Milligram per cubic meter; a measure of the concentration of a chemical in a known 
volume (a cubic meter) of air, soil, or water.  
 
Migration  
Moving from one location to another.  
 
Minimal risk level (MRL)  
An ATSDR estimate of daily human exposure to a hazardous substance at or below 
which that substance is unlikely to pose a measurable risk of harmful (adverse), 
noncancerous effects. MRLs are calculated for a route of exposure (inhalation or oral) 
over a specified time period (acute, intermediate, or chronic). MRLs should not be used 
as predictors of harmful (adverse) health effects [see reference dose].  
 
Morbidity  
State of being ill or diseased. Morbidity is the occurrence of a disease or condition that 
alters health and quality of life.  
 
Mortality  
Death. Usually the cause (a specific disease, a condition, or an injury) is stated.  
 
 
 
B-11 
Mutagen  
A substance that causes mutations (genetic damage).  
 
Mutation  
A change (damage) to the DNA, genes, or chromosomes of living organisms.  
 
National Priorities List for Uncontrolled Hazardous Waste Sites (National Priorities 
List or NPL)  
EPA’s list of the most serious uncontrolled or abandoned hazardous waste sites in the 
United States. The NPL is updated on a regular basis. 
 
National Toxicology Program (NTP) 
Part of the Department of Health and Human Services. NTP develops and carries out 
tests to predict whether a chemical will cause harm to humans.  
 
No apparent public health hazard  
A category used in ATSDR’s public health assessments for sites where human exposure 
to contaminated media might be occurring, might have occurred in the past, or might 
occur in the future, but where the exposure is not expected to cause any harmful health 
effects.  
 
No-observed-adverse-effect level (NOAEL)  
The highest tested dose of a substance that has been reported to have no harmful 
(adverse) health effects on people or animals.  
 
No public health hazard  
A category used in ATSDR's public health assessment documents for sites where people 
have never and will never come into contact with harmful amounts of site-related 
substances.  
 
NPL [see National Priorities List for Uncontrolled Hazardous Waste Sites] 
 
Physiologically based pharmacokinetic model (PBPK model)  
A computer model that describes what happens to a chemical in the body. This model 
describes how the chemical gets into the body, where it goes in the body, how it is 
changed by the body, and how it leaves the body.  
 
Pica  
A craving to eat nonfood items, such as dirt, paint chips, and clay. Some children exhibit 
pica-related behavior.  
 
Plume  
A volume of a substance that moves from its source to places farther away from the 
source. Plumes can be described by the volume of air or water they occupy and the 
direction they move. For example, a plume can be a column of smoke from a chimney or 
a substance moving with groundwater.  
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Point of exposure  
The place where someone can come into contact with a substance present in the 
environment [see exposure pathway].  
 
Population  
A group or number of people living within a specified area or sharing similar 
characteristics (such as occupation or age).  
 
Potentially responsible party (PRP)  
A company, government, or person legally responsible for cleaning up the pollution at a 
hazardous waste site under Superfund. There may be more than one PRP for a particular 
site.  
 
ppb  
Parts per billion.  
 
ppm  
Parts per million.  
 
Prevalence  
The number of existing disease cases in a defined population during a specific time 
period [contrast with incidence].  
 
Prevalence survey  
The measure of the current level of disease(s) or symptoms and exposures through a 
questionnaire that collects self-reported information from a defined population.  
 
Prevention  
Actions that reduce exposure or other risks, keep people from getting sick, or keep 
disease from getting worse.  
 
Public availability session  
An informal, drop-by meeting at which community members can meet one-on-one with 
ATSDR staff members to discuss health and site-related concerns. 
 
Public comment period  
An opportunity for the public to comment on agency findings or proposed activities 
contained in draft reports or documents. The public comment period is a limited time 
period during which comments will be accepted.  
 
Public health action  
A list of steps to protect public health.  
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Public health advisory  
A statement made by ATSDR to EPA or a state regulatory agency that a release of 
hazardous substances poses an immediate threat to human health. The advisory includes 
recommended measures to reduce exposure and reduce the threat to human health.  
 
Public health assessment (PHA)  
An ATSDR document that examines hazardous substances, health outcomes, and 
community concerns at a hazardous waste site to determine whether people could be 
harmed from coming into contact with those substances. The PHA also lists actions that 
need to be taken to protect public health [compare with health consultation].  
 
Public health hazard  
A category used in ATSDR's public health assessments for sites that pose a public health 
hazard because of long-term exposures (greater than 1 year) to sufficiently high levels of 
hazardous substances or radionuclides that could result in harmful health effects.  
 
Public health hazard categories  
Public health hazard categories are statements about whether people could be harmed by 
conditions present at the site in the past, present, or future. One or more hazard categories 
might be appropriate for each site. The five public health hazard categories are no public 
health hazard, no apparent public health hazard, indeterminate public health hazard, 
public health hazard, and urgent public health hazard.  
 
Public health statement 
The first chapter of an ATSDR toxicological profile. The public health statement is a 
summary written in words that are easy to understand. The public health statement 
explains how people might be exposed to a specific substance and describes the known 
health effects of that substance.  
 
Public health surveillance 
The ongoing, systematic collection, analysis, and interpretation of health data. This 
activity also involves timely dissemination of the data and use for public health programs. 
 
Public meeting  
A public forum with community members for communication about a site.  
 
Radioisotope  
An unstable or radioactive isotope (form) of an element that can change into another 
element by giving off radiation.  
 
Radionuclide  
Any radioactive isotope (form) of any element.  
 
RCRA [see Resource Conservation and Recovery Act (1976, 1984)]  
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Receptor population  
People who could come into contact with hazardous substances [see exposure pathway].  
 
Reference dose (RfD)  
An EPA estimate, with uncertainty or safety factors built in, of the daily lifetime dose of 
a substance that is unlikely to cause harm in humans.  
 
Registry  
A systematic collection of information on persons exposed to a specific substance or 
having specific diseases [see exposure registry and disease registry].  
 
Remedial investigation  
The CERCLA process of determining the type and extent of hazardous material 
contamination at a site.  
 
Resource Conservation and Recovery Act (1976, 1984) (RCRA) 
This Act regulates management and disposal of hazardous wastes currently generated, 
treated, stored, disposed of, or distributed.  
 
RFA  
RCRA Facility Assessment. An assessment required by RCRA to identify potential and 
actual releases of hazardous chemicals.  
 
RfD [see reference dose] 
 
Risk  
The probability that something will cause injury or harm.  
 
Risk reduction  
Actions that can decrease the likelihood that individuals, groups, or communities will 
experience disease or other health conditions.  
 
Risk communication  
The exchange of information to increase understanding of health risks.  
 
Route of exposure  
The way people come into contact with a hazardous substance. Three routes of exposure 
are breathing [inhalation], eating or drinking [ingestion], or contact with the skin [dermal 
contact].  
 
Safety factor [see uncertainty factor]  
 
SARA [see Superfund Amendments and Reauthorization Act]  
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Sample  
A portion or piece of a whole. A selected subset of a population or subset of whatever is 
being studied. For example, in a study of people the sample is a number of people chosen 
from a larger population [see population]. An environmental sample (for example, a 
small amount of soil or water) might be collected to measure contamination in the 
environment at a specific location.  
 
Sample size  
The number of units chosen from a population or an environment.  
 
Solvent  
A liquid capable of dissolving or dispersing another substance (for example, acetone or 
mineral spirits).  
 
Source of contamination  
The place where a hazardous substance comes from, such as a landfill, waste pond, 
incinerator, storage tank, or drum. A source of contamination is the first part of an 
exposure pathway.  
 
Special populations  
People who might be more sensitive or susceptible to exposure to hazardous substances 
because of factors such as age, occupation, sex, or behaviors (for example, cigarette 
smoking). Children, pregnant women, and older people are often considered special 
populations.  
 
Stakeholder  
A person, group, or community who has an interest in activities at a hazardous waste site.  
 
Statistics  
A branch of mathematics that deals with collecting, reviewing, summarizing, and 
interpreting data or information. Statistics are used to determine whether differences 
between study groups are meaningful.  
 
Substance  
A chemical.  
 
Substance-specific applied research  
A program of research designed to fill important data needs for specific hazardous 
substances identified in ATSDR's toxicological profiles. Filling these data needs would 
allow more accurate assessment of human risks from specific substances contaminating 
the environment. This research might include human studies or laboratory experiments to 
determine health effects resulting from exposure to a given hazardous substance.  
 
Superfund [see Comprehensive Environmental Response, Compensation, and Liability 
Act of 1980 (CERCLA) and Superfund Amendments and Reauthorization Act (SARA)  
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Superfund Amendments and Reauthorization Act (SARA)  
In 1986, SARA amended the Comprehensive Environmental Response, Compensation, 
and Liability Act of 1980 (CERCLA) and expanded the health-related responsibilities of 
ATSDR. CERCLA and SARA direct ATSDR to look into the health effects from 
substance exposures at hazardous waste sites and to perform activities including health 
education, health studies, surveillance, health consultations, and toxicological profiles.  
 
Surface water  
Water on the surface of the earth, such as in lakes, rivers, streams, ponds, and springs 
[compare with groundwater].  
 
Surveillance [see public health surveillance]  
 
Survey  
A systematic collection of information or data. A survey can be conducted to collect 
information from a group of people or from the environment. Surveys of a group of 
people can be conducted by telephone, by mail, or in person. Some surveys are done by 
interviewing a group of people [see prevalence survey].  
 
Synergistic effect  
A biologic response to multiple substances where one substance worsens the effect of 
another substance. The combined effect of the substances acting together is greater than 
the sum of the effects of the substances acting by themselves [see additive effect and 
antagonistic effect].  
 
Teratogen  
A substance that causes defects in development between conception and birth. A 
teratogen is a substance that causes a structural or functional birth defect.  
 
Toxic agent  
Chemical or physical (for example, radiation, heat, cold, microwaves) agents that, under 
certain circumstances of exposure, can cause harmful effects to living organisms.  
 
Toxicological profile  
An ATSDR document that examines, summarizes, and interprets information about a 
hazardous substance to determine harmful levels of exposure and associated health 
effects. A toxicological profile also identifies significant gaps in knowledge on the 
substance and describes areas where further research is needed.  
 
Toxicology  
The study of the harmful effects of substances on humans or animals.  
 
Tumor  
An abnormal mass of tissue that results from excessive cell division that is uncontrolled 
and progressive. Tumors perform no useful body function. Tumors can be either benign 
(not cancer) or malignant (cancer).  
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Uncertainty factor  
Mathematical adjustments for reasons of safety when knowledge is incomplete. For 
example, factors used in the calculation of doses that are not harmful (adverse) to people. 
These factors are applied to the lowest-observed-adverse-effect-level (LOAEL) or the no-
observed-adverse-effect-level (NOAEL) to derive a minimal risk level (MRL). 
Uncertainty factors are used to account for variations in people's sensitivity, for 
differences between animals and humans, and for differences between a LOAEL and a 
NOAEL. Scientists use uncertainty factors when they have some, but not all, the 
information from animal or human studies to decide whether an exposure will cause harm 
to people [also sometimes called a safety factor].  
 
Urgent public health hazard  
A category used in ATSDR's public health assessments for sites where short-term 
exposures (less than 1 year) to hazardous substances or conditions could result in harmful 
health effects that require rapid intervention.  
 
Volatile organic compounds (VOCs)  
Organic compounds that evaporate readily into the air. VOCs include substances such as 
benzene, toluene, methylene chloride, and methyl chloroform.  
 
 
Other glossaries and dictionaries: 
Environmental Protection Agency (http://www.epa.gov/OCEPAterms/) 
 
National Center for Environmental Health (CDC) 
(http://www.cdc.gov/nceh/dls/report/glossary.htm) 
 
National Library of Medicine (NIH) 
(http://www.nlm.nih.gov/medlineplus/mplusdictionary.html) 
 
For more information on the work of ATSDR, please contact: 
 
Office of Policy and External Affairs 
Agency for Toxic Substances and Disease Registry 
1600 Clifton Road, N.E. (MS E-60) 
Atlanta, GA 30333 
Telephone: (404) 498-0080  
 
 
 
 
 
 
